xCures

The convergence of genomics, precision medicine, and AI have created an unprecedented moment in the world of oncology. But the drug-centric way in which treatments are developed and the haphazard way in which knowledge about those treatments is captured and delivered to the point of care does not serve patients well. xCures is changing that, with an AI-based precision oncology platform that tightly integrates cancer research and care.

The xCures platform runs a perpetual trial that captures Real World Evidence (RWE) to continuously learn from all patients, on all treatments, all the time. It coordinates treatment recommendations across all patients and institutions to match patients with the treatments that work. And it packages RWE for use by stakeholders across oncology, slashing the time and cost of drug development and saving lives.

xCures headquartered in United States, North America, operates in the Biotechnology, Artificial Intelligence (AI), Machine Learning, Health Care, Pharmaceutical, Medical, Oncology sector. The company focuses on Biotechnology and has secured $3.3B in funding across 252 round(s). With a team of 51-100 employees, xCures is actively contributing to advancements in Biotechnology. Their latest funding round, Convertible Note - xCures, raised $Unknown amount. Discover more about their projects, partnerships, and impact on our platform.